WEBULL
News
IPDQF
0.012
NaN%
--
Impedimed Seeks ASX Quotation for Executive Remuneration Shares
TipRanks · 12/23/2025 05:37
Bell Potter Sticks to Its Buy Rating for Impedimed Limited (IPDQF)
TipRanks · 12/11/2025 23:16
ImpediMed Expands U.S. Insurance Coverage for Lymphoedema Assessment
TipRanks · 12/03/2025 21:36
ImpediMed Strengthens Financial Position with R&D Tax Incentive Refund
TipRanks · 11/24/2025 06:37
ImpediMed Limited Successfully Concludes Annual General Meeting with All Resolutions Passed
TipRanks · 11/18/2025 03:37
ImpediMed’s 2025 AGM: Advancing Healthcare Standards
TipRanks · 11/18/2025 01:28
Impedimed Limited Reports Strong Growth and Strategic Focus at 2025 AGM
TipRanks · 11/18/2025 01:28
ImpediMed Director Increases Shareholding in Strategic Move
TipRanks · 11/06/2025 11:59
ImpediMed Director Increases Stake Through Share Acquisition
TipRanks · 11/06/2025 11:59
ImpediMed Director Increases Shareholding Through Fee Conversion
TipRanks · 11/06/2025 11:58
Impedimed Director Increases Shareholding Through Fee Conversion
TipRanks · 11/06/2025 11:58
Impedimed Limited (IPDQF) Receives a Buy from Morgans
TipRanks · 11/06/2025 03:56
Impedimed Limited Issues Shares to Non-Executive Directors
TipRanks · 11/05/2025 22:45
Impedimed Limited Issues Shares Under Executive Share Plan
TipRanks · 11/05/2025 22:45
Canaccord Genuity Sticks to Their Buy Rating for Impedimed Limited (IPDQF)
TipRanks · 10/31/2025 13:25
Impedimed Limited’s Earnings Call: Mixed Sentiments and Strategic Insights
TipRanks · 10/31/2025 00:39
ImpediMed Limited Reports Record Revenue in Q1 FY26
TipRanks · 10/30/2025 05:01
ImpediMed Limited Releases Q1 FY26 Investor Presentation
TipRanks · 10/29/2025 22:37
ImpediMed Reports Record Revenue and Expands Market Presence in Q1 FY26
TipRanks · 10/29/2025 22:37
ImpediMed Limited Launches Investor Hub and Prepares for Q1 FY26 Results
TipRanks · 10/24/2025 05:48
More
Webull provides a variety of real-time IPDQF stock news. You can receive the latest news about Impedimed through multiple platforms. This information may help you make smarter investment decisions.
About IPDQF
ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. Its SOZO Applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp Analysis, and HF-Dex Analysis for Heart Failure. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.